Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies
Recent early-stage clinical trials evaluating the adoptive transfer of patient CD8+ T-cells re-directed with antigen receptors recognising tumours have shown very encouraging results. These reports provide strong support for further development of the therapeutic concept as a curative cancer treatme...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00221/full |
| _version_ | 1811242063883141120 |
|---|---|
| author | Angharad eLloyd Owen Niall Vickery Bruno eLaugel |
| author_facet | Angharad eLloyd Owen Niall Vickery Bruno eLaugel |
| author_sort | Angharad eLloyd |
| collection | DOAJ |
| description | Recent early-stage clinical trials evaluating the adoptive transfer of patient CD8+ T-cells re-directed with antigen receptors recognising tumours have shown very encouraging results. These reports provide strong support for further development of the therapeutic concept as a curative cancer treatment. In this respect combining the adoptive transfer of tumour-specific T-cells with therapies that increase their anti-tumour capacity is viewed as a promising strategy to improve treatment outcome. The ex-vivo genetic engineering step that underlies T-cell re-direction offers a unique angle to combine antigen receptor delivery with the targeting of cell intrinsic pathways that restrict T-cell effector functions. Recent progress in genome editing technologies such as protein- and RNA-guided endonucleases raise the possibility of disrupting gene expression in T-cells in order to enhance effector functions or to bypass tumour immune suppression. This approach would avoid the systemic administration of compounds that disrupt immune homeostasis, potentially avoiding autoimmune adverse effects, and could improve the efficacy of T-cell based adoptive therapies. |
| first_indexed | 2024-04-12T13:46:24Z |
| format | Article |
| id | doaj.art-1b03f22d1d004fc1ace40f2c7635d2af |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T13:46:24Z |
| publishDate | 2013-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1b03f22d1d004fc1ace40f2c7635d2af2022-12-22T03:30:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242013-08-01410.3389/fimmu.2013.0022153628Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapiesAngharad eLloyd0Owen Niall Vickery1Bruno eLaugel2Cardiff University School of MedicineCardiff University School of MedicineCardiff University School of MedicineRecent early-stage clinical trials evaluating the adoptive transfer of patient CD8+ T-cells re-directed with antigen receptors recognising tumours have shown very encouraging results. These reports provide strong support for further development of the therapeutic concept as a curative cancer treatment. In this respect combining the adoptive transfer of tumour-specific T-cells with therapies that increase their anti-tumour capacity is viewed as a promising strategy to improve treatment outcome. The ex-vivo genetic engineering step that underlies T-cell re-direction offers a unique angle to combine antigen receptor delivery with the targeting of cell intrinsic pathways that restrict T-cell effector functions. Recent progress in genome editing technologies such as protein- and RNA-guided endonucleases raise the possibility of disrupting gene expression in T-cells in order to enhance effector functions or to bypass tumour immune suppression. This approach would avoid the systemic administration of compounds that disrupt immune homeostasis, potentially avoiding autoimmune adverse effects, and could improve the efficacy of T-cell based adoptive therapies.http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00221/fullCancerT-cellsimmune checkpointsGenome editingCell therapies |
| spellingShingle | Angharad eLloyd Owen Niall Vickery Bruno eLaugel Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies Frontiers in Immunology Cancer T-cells immune checkpoints Genome editing Cell therapies |
| title | Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies |
| title_full | Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies |
| title_fullStr | Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies |
| title_full_unstemmed | Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies |
| title_short | Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies |
| title_sort | beyond the antigen receptor editing the genome of t cells for cancer adoptive cellular therapies |
| topic | Cancer T-cells immune checkpoints Genome editing Cell therapies |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00221/full |
| work_keys_str_mv | AT angharadelloyd beyondtheantigenreceptoreditingthegenomeoftcellsforcanceradoptivecellulartherapies AT owenniallvickery beyondtheantigenreceptoreditingthegenomeoftcellsforcanceradoptivecellulartherapies AT brunoelaugel beyondtheantigenreceptoreditingthegenomeoftcellsforcanceradoptivecellulartherapies |